FDA SLAPS PARTIAL HOLD ON CURIS LEUKEMIA STUDY
Curis’ phase 1/2a leukaemia study is the latest to join the club of FDA clinical holds, following the death of a trial participant. The Massachusetts-based biotech announced the partial clinical hold today, citing the FDA’s request for additional safety and efficacy data, including more information about the patient death. The trial on pause is TakeAim Leukemia, which […]
NOVARTIS UNVEILS MAJOR RE-ORG
Novartis has announced a new organizational structure and operating model, with an eye on innovation and growth — as well as targeted savings of at least $1 billion by 2024. The Swiss giant’s new “simplified structure and operational set-up” will integrate the pharmaceuticals and oncology business units, creating two separate commercial organizations with a stronger geographic focus […]
PARSORTIX SYSTEM IDENTIFIES KEY DRUG TARGETS IN CANCER METASTASIS
The study demonstrates the ability of the Parsortix system to isolate circulating tumour cells, targeting the metastatic spread of cancer. Liquid biopsy company Angle has announced the results of work undertaken in preclinical models of metastatic breast cancer (MBC), where specific genes involved in the metastatic process have been identified. The study adds to the […]
POSITIVE RESULTS FOR CEREVANCE’S PARKINSON’S DRUG
In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s symptoms recur despite medication Cerevance has announced positive phase 2 trial results for the company’s first-in-class, once-a-day, orally-administered compound treating Parkinson’s disease. The company is a private, clinical-stage drug discovery and development company focused on central nervous […]
MISSION THERAPEUTICS LAUNCHES CLINICAL TRIAL FOR KIDNEY DISEASE THERAPY
MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trial Mission Therapeutics has been granted approval to take its lead USP30 deubiquitinating enzyme (DUB) inhibitor – MTX652 – into a clinical study. The mitochondrial-associated DUB removes ubiquitin, which is what damaged mitochondria are labelled with. This inhibits the degradation […]